Inhibition of human platelet aggregation by parathyroid hormone: Is cyclic AMP implicated?

Anela Benigni, Manuela Livio, Patrizia Dodesini, Arrigo Schieppati, Mario Panigada, Giuliano Mecca, Giovanni De Gaetano, Giuseppe Remuzzi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Parathyroid hormone (PTH) is a polypeptide which in different in vitro systems raises intracellular cyclic AMP (cAMP) levels via adenyl cyclase activation and stimulates Ca2+ transport across cell membranes. We tested whether, on the basis of this mechanism. PTH would inhibit human platelet aggregation. The latter was tested in vitro by a photometric technique. Platelet aggregation induced by the calcium ionophore A 23187 was inhibited by PTH at concentrations (0.5-3 USP U/ml) similar to those effective in other in vitro systems. Higher concentrations of PTH were required to prevent aggregation initiated by adenosinc-5'-diphosphate, arachidonic acid, or platelet-aggregating factor. The terminal synthetic fragment 1-34 b PTH was ineffective against all aggregation stimuli. The antiaggregating effect of PTH was potentiated by verapamil and theophylline and was additive to that of PGI2. However. PTH did not appear to increase platelet cAMP levels and was not counteracted by an inhibitor of platelet adenyl cyclase. It is therefore unlikely that PTH inhibits platelet aggregation through an adenyl cyclase stimulated increase ofcAMP. Since PTH levels are markedly increased in uremic plasma, it might contribute to the defective platelet function and the bleeding tendency frequently occurring in uremic patients.

Original languageEnglish
Pages (from-to)243-247
Number of pages5
JournalAmerican Journal of Nephrology
Volume5
Issue number4
DOIs
Publication statusPublished - 1985

Fingerprint

Parathyroid Hormone
Platelet Aggregation
Cyclic AMP
Adenylyl Cyclases
Blood Platelets
Calcium Ionophores
Diphosphates
Platelet Activating Factor
Platelet Aggregation Inhibitors
Calcimycin
Epoprostenol
Theophylline
Verapamil
Arachidonic Acid
Cell Membrane
Hemorrhage
Peptides

Keywords

  • cAMP
  • Parathyroid hormone
  • Platelet aggregation

ASJC Scopus subject areas

  • Nephrology

Cite this

Inhibition of human platelet aggregation by parathyroid hormone : Is cyclic AMP implicated? / Benigni, Anela; Livio, Manuela; Dodesini, Patrizia; Schieppati, Arrigo; Panigada, Mario; Mecca, Giuliano; De Gaetano, Giovanni; Remuzzi, Giuseppe.

In: American Journal of Nephrology, Vol. 5, No. 4, 1985, p. 243-247.

Research output: Contribution to journalArticle

Benigni, Anela ; Livio, Manuela ; Dodesini, Patrizia ; Schieppati, Arrigo ; Panigada, Mario ; Mecca, Giuliano ; De Gaetano, Giovanni ; Remuzzi, Giuseppe. / Inhibition of human platelet aggregation by parathyroid hormone : Is cyclic AMP implicated?. In: American Journal of Nephrology. 1985 ; Vol. 5, No. 4. pp. 243-247.
@article{bffc6be6dce9429387e05e7c8e830bde,
title = "Inhibition of human platelet aggregation by parathyroid hormone: Is cyclic AMP implicated?",
abstract = "Parathyroid hormone (PTH) is a polypeptide which in different in vitro systems raises intracellular cyclic AMP (cAMP) levels via adenyl cyclase activation and stimulates Ca2+ transport across cell membranes. We tested whether, on the basis of this mechanism. PTH would inhibit human platelet aggregation. The latter was tested in vitro by a photometric technique. Platelet aggregation induced by the calcium ionophore A 23187 was inhibited by PTH at concentrations (0.5-3 USP U/ml) similar to those effective in other in vitro systems. Higher concentrations of PTH were required to prevent aggregation initiated by adenosinc-5'-diphosphate, arachidonic acid, or platelet-aggregating factor. The terminal synthetic fragment 1-34 b PTH was ineffective against all aggregation stimuli. The antiaggregating effect of PTH was potentiated by verapamil and theophylline and was additive to that of PGI2. However. PTH did not appear to increase platelet cAMP levels and was not counteracted by an inhibitor of platelet adenyl cyclase. It is therefore unlikely that PTH inhibits platelet aggregation through an adenyl cyclase stimulated increase ofcAMP. Since PTH levels are markedly increased in uremic plasma, it might contribute to the defective platelet function and the bleeding tendency frequently occurring in uremic patients.",
keywords = "cAMP, Parathyroid hormone, Platelet aggregation",
author = "Anela Benigni and Manuela Livio and Patrizia Dodesini and Arrigo Schieppati and Mario Panigada and Giuliano Mecca and {De Gaetano}, Giovanni and Giuseppe Remuzzi",
year = "1985",
doi = "10.1159/000166942",
language = "English",
volume = "5",
pages = "243--247",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Inhibition of human platelet aggregation by parathyroid hormone

T2 - Is cyclic AMP implicated?

AU - Benigni, Anela

AU - Livio, Manuela

AU - Dodesini, Patrizia

AU - Schieppati, Arrigo

AU - Panigada, Mario

AU - Mecca, Giuliano

AU - De Gaetano, Giovanni

AU - Remuzzi, Giuseppe

PY - 1985

Y1 - 1985

N2 - Parathyroid hormone (PTH) is a polypeptide which in different in vitro systems raises intracellular cyclic AMP (cAMP) levels via adenyl cyclase activation and stimulates Ca2+ transport across cell membranes. We tested whether, on the basis of this mechanism. PTH would inhibit human platelet aggregation. The latter was tested in vitro by a photometric technique. Platelet aggregation induced by the calcium ionophore A 23187 was inhibited by PTH at concentrations (0.5-3 USP U/ml) similar to those effective in other in vitro systems. Higher concentrations of PTH were required to prevent aggregation initiated by adenosinc-5'-diphosphate, arachidonic acid, or platelet-aggregating factor. The terminal synthetic fragment 1-34 b PTH was ineffective against all aggregation stimuli. The antiaggregating effect of PTH was potentiated by verapamil and theophylline and was additive to that of PGI2. However. PTH did not appear to increase platelet cAMP levels and was not counteracted by an inhibitor of platelet adenyl cyclase. It is therefore unlikely that PTH inhibits platelet aggregation through an adenyl cyclase stimulated increase ofcAMP. Since PTH levels are markedly increased in uremic plasma, it might contribute to the defective platelet function and the bleeding tendency frequently occurring in uremic patients.

AB - Parathyroid hormone (PTH) is a polypeptide which in different in vitro systems raises intracellular cyclic AMP (cAMP) levels via adenyl cyclase activation and stimulates Ca2+ transport across cell membranes. We tested whether, on the basis of this mechanism. PTH would inhibit human platelet aggregation. The latter was tested in vitro by a photometric technique. Platelet aggregation induced by the calcium ionophore A 23187 was inhibited by PTH at concentrations (0.5-3 USP U/ml) similar to those effective in other in vitro systems. Higher concentrations of PTH were required to prevent aggregation initiated by adenosinc-5'-diphosphate, arachidonic acid, or platelet-aggregating factor. The terminal synthetic fragment 1-34 b PTH was ineffective against all aggregation stimuli. The antiaggregating effect of PTH was potentiated by verapamil and theophylline and was additive to that of PGI2. However. PTH did not appear to increase platelet cAMP levels and was not counteracted by an inhibitor of platelet adenyl cyclase. It is therefore unlikely that PTH inhibits platelet aggregation through an adenyl cyclase stimulated increase ofcAMP. Since PTH levels are markedly increased in uremic plasma, it might contribute to the defective platelet function and the bleeding tendency frequently occurring in uremic patients.

KW - cAMP

KW - Parathyroid hormone

KW - Platelet aggregation

UR - http://www.scopus.com/inward/record.url?scp=0022257001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022257001&partnerID=8YFLogxK

U2 - 10.1159/000166942

DO - 10.1159/000166942

M3 - Article

C2 - 2996352

AN - SCOPUS:0022257001

VL - 5

SP - 243

EP - 247

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 4

ER -